Circulating DNA in Serum as a Tumor Marker in Precancerous Lesions of the Cervix in Mexican Women

Alcántara-Quintana Luz Eugenia
{"title":"Circulating DNA in Serum as a Tumor Marker in Precancerous Lesions of the Cervix in Mexican Women","authors":"Alcántara-Quintana Luz Eugenia","doi":"10.31031/nacs.2021.06.000629","DOIUrl":null,"url":null,"abstract":"Introduction: Cervical cancer is the fourth leading cause of death in the world. This poor prognosis is due to the fact that in two out of three cases the disease is diagnosed in advanced stages. Consequently, advances in detection methods can lead to early diagnosis of the disease and consequently to an improved prognosis. Methods based on serum-based tumor markers are a promising tool for early diagnosis and in general for biochemical screening of cancer patients. They also offer the added value of being non-invasive methods. Evidence has been found for the release of cellular DNA into the blood, so its quantification has the potential to serve as a tumor marker. If this DNA is detected in serum, it can reflect tumor size, viral load and response to treatment. Objective: To determine the amount of circulating DNA in serum of patients with precancerous lesions. Methods: The study was carried out with 40 healthy women and 120 women with precancerous lesions, who attended gynecological-obstetric care. Of the 120, 60 had low-grade lesions and 60 had high-grade lesions. All participants had a blood sample taken for determination of circulating DNA in serum. Specific oligonucleotides were used to determine not only the amount of circulating DNA in the patient, but also the amount of viral DNA. Papillomavirus detection/genotyping was performed by qPCR. One third of the patients showed at least one high-risk genotype. Conclusion: In this study, differential quantification of both patient and viral circulating DNA was observed.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Novel approaches in cancer study","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/nacs.2021.06.000629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cervical cancer is the fourth leading cause of death in the world. This poor prognosis is due to the fact that in two out of three cases the disease is diagnosed in advanced stages. Consequently, advances in detection methods can lead to early diagnosis of the disease and consequently to an improved prognosis. Methods based on serum-based tumor markers are a promising tool for early diagnosis and in general for biochemical screening of cancer patients. They also offer the added value of being non-invasive methods. Evidence has been found for the release of cellular DNA into the blood, so its quantification has the potential to serve as a tumor marker. If this DNA is detected in serum, it can reflect tumor size, viral load and response to treatment. Objective: To determine the amount of circulating DNA in serum of patients with precancerous lesions. Methods: The study was carried out with 40 healthy women and 120 women with precancerous lesions, who attended gynecological-obstetric care. Of the 120, 60 had low-grade lesions and 60 had high-grade lesions. All participants had a blood sample taken for determination of circulating DNA in serum. Specific oligonucleotides were used to determine not only the amount of circulating DNA in the patient, but also the amount of viral DNA. Papillomavirus detection/genotyping was performed by qPCR. One third of the patients showed at least one high-risk genotype. Conclusion: In this study, differential quantification of both patient and viral circulating DNA was observed.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清循环DNA作为墨西哥妇女宫颈癌前病变的肿瘤标志物
简介:癌症是世界第四大死亡原因。这种不良预后是由于三分之二的病例被诊断为晚期。因此,检测方法的进步可以导致疾病的早期诊断,从而改善预后。基于血清的肿瘤标志物的方法是癌症患者早期诊断和生化筛查的一种很有前途的工具。它们还提供了非侵入性方法的附加值。已经发现细胞DNA释放到血液中的证据,因此其定量具有作为肿瘤标志物的潜力。如果在血清中检测到这种DNA,它可以反映肿瘤的大小、病毒载量和对治疗的反应。目的:测定癌前病变患者血清循环DNA含量。方法:对40名健康女性和120名接受妇科产科护理的癌前病变女性进行研究。在120例中,60例为低度病变,60例有高度病变。所有参与者都采集了血样以测定血清中的循环DNA。特异性寡核苷酸不仅用于测定患者体内循环DNA的量,还用于测定病毒DNA的量。通过qPCR进行乳头瘤病毒检测/基因分型。三分之一的患者显示出至少一种高危基因型。结论:在本研究中,观察到患者和病毒循环DNA的差异定量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Applications of Protein Nanomaterials in Cancer Therapies Anti-Inflammatory Responses of Natural Products in Wounds and Cancer Infections Antimicrobial Peptides in Bladder Cancer The Neoplastic Tonnage-Pleomorphic Xanthoastrocytoma Current Therapeutics and Future Perspectives for Treatment of Advanced BRAF V600 mutant Melanoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1